HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment
Clin Med Res. 2023 Sep;21(3):155-158. doi: 10.3121/cmr.2023.1804.ABSTRACTHere we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating fac...
Source: Clinical Medicine and Research - November 20, 2023 Category: General Medicine Authors: Allison J Geiger Demet Gokalp Yasar Kajal V Sitwala Source Type: research
